3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
2
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Autoimmune Diseases
1
Interventions
Ipilimumab
4
tremelimumab
1
tilsotolimod
1
durvalumab
1
Vemurafenib
1
Vaccination
1
Surgical Procedures, Operative
1
Nivolumab
1
Melphalan
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Immunotherapy
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled